Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Aug 12;13(8):762.
doi: 10.3390/antibiotics13080762.

Rapid Reversal of Carbapenemase-Producing Pseudomonas aeruginosa Epidemiology from blaVIM- to blaNDM-harbouring Isolates in a Greek Tertiary Care Hospital

Efthymia Protonotariou  1 , Georgios Meletis  1 , Nikoletta Vlachodimou  1 , Andigoni Malousi  2 , Areti Tychala  1 , Charikleia Katsanou  1 , Aikaterini Daviti  1 , Paraskevi Mantzana  1 , Lemonia Skoura  1
Affiliations

Rapid Reversal of Carbapenemase-Producing Pseudomonas aeruginosa Epidemiology from blaVIM- to blaNDM-harbouring Isolates in a Greek Tertiary Care Hospital

Efthymia Protonotariou et al. Antibiotics (Basel). .

Abstract

Carbapenemase-producing Pseudomonas aeruginosa strains present a specific geographical distribution regarding the type of carbapenemase-encoding genes that they harbor. For more than twenty years, VIM-type enzymes were the only major carbapenemases that were detected among P. aeruginosa isolates in Greece until the emergence of NDM-1-encoding P. aeruginosa in early 2023. In the present study, we present the rapid reversal of the carbapenemase-producing P. aeruginosa epidemiology from blaVIM- to blaNDM-harbouring isolates that occurred in our hospital since then. Between January 2023 and February 2024, 139 isolates tested positive for carbapenemase production with the NG-Test CARBA 5 immunochromatographic assay. Eight isolates were processed with the Hybrispot antimicrobial resistance direct flow chip molecular assay, and the first NDM-producing isolate was further analyzed through whole genome sequencing and bioinformatics analysis. Multiple resistance genes were detected by molecular techniques in accordance with the extensively drug-resistant phenotype. The isolate that was subjected to whole-genome sequencing belonged to the P. aeruginosa high-risk clone ST308, and the blaNDM was located in the chromosome in accordance with previously reported data. During the study period, NDM-producing isolates were increasingly detected, and only five months after their emergence, they overcame VIM producers. Our results indicate the potential of this new clone to spread rapidly and predominate within healthcare institutions, further restricting the already limited treatment options.

Keywords: NDM; Pseudomonas aeruginosa; VIM; carbapenem resistance; carbapenemases; hospital infections.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflicts of interest.

Figures

Figure 1
Figure 1
Reversal of the carbapenemase-producing P. aeruginosa epidemiology from VIM to NDM in the hospital setting.
Figure 2
Figure 2
The 2323 bp contig including blaNDM-1 and the neighboring IS91 family transposase.
See this image and copyright information in PMC

References

    1. WHO . WHO Bacterial Priority Pathogens List, 2024: Bacterial Pathogens of Public Health Importance to Guide Research, Development and Strategies to Prevent and Control Antimicrobial Resistance. World Health Organization; Geneva, Switzerland: 2024.
    1. Antimicrobial Resistance Surveillance in Europe 2023–2021 Data. European Centre for Disease Prevention and Control and World Health Organization; Stockholm, Sweden: 2023.
    1. Meletis G., Exindari M., Vavatsi N., Sofianou D., Diza E. Mechanisms responsible for the emergence of carbapenem resistance in Pseudomonas aeruginosa. Hippokratia. 2012;16:303–307. - PMC - PubMed
    1. Partridge S.R., Kwong S.M., Firth N., Jensen S.O. Mobile Genetic Elements Associated with Antimicrobial Resistance. Clin. Microbio. Rev. 2018;31:e00088-17. doi: 10.1128/CMR.00088-17. - DOI - PMC - PubMed
    1. Horcajada J.P., Montero M., Oliver A., Sorlí L., Luque S., Gómez-Zorrilla S., Benito N., Grau S. Epidemiology and Treatment of Multidrug-Resistant and Extensively Drug-Resistant Pseudomonas aeruginosa Infections. Clin. Microbiol. Rev. 2019;32:e00031-19. doi: 10.1128/CMR.00031-19. - DOI - PMC - PubMed

LinkOut - more resources